Publications
350 publications
Sort by: Date / Relevance
GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease
The National Health Care Institute has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product ...
GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria
The National Health Care Institute has completed its assessment whether givosiran (Givlaari®) is interchangeable with a product ...
GVS assessment oxybutynin intravesical solution (Vesolox®)
Zorginstituut Nederland has completed its assessment whether oxybutynin intravesical solution (Vesolox®) 1mg/ml is ...
GVS advice mexiletine (Namuscla®)
The National Health Care Institute has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable ...
Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism
Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...
GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis
The National Health Care Institute has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product ...
GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...
GVS assessment - extension of further conditions for nintedanib (Ofev®)
The National Health Care Institute has completed its assessment of the possible extension of the further conditions for ...
Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...
GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
The National Health Care Institute has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or ...